CRISPR CLINICAL TRIALS

Medicine is changing.

New CRISPR gene editing clinical studies are rapidly emerging and we think a comprehensive overview is valuable to help keep track of them all.

CRISPR is the hot new rapidly rising gene editing tool but we also include clinical trials of other gene editing modalities like the Zinc Finger Nucleases, TALENs, MegaTALS, CAS-CLOVER, MegaNucleases and any new variants that will be out there in the future. We will keep updating our overview.

Check already now the world's-first clinical trial for a CRISPR-Cas3 phage therapy for treatment of urinary tract infections, developed by Locus BioSciences and get all the details about their unique technology from this interview with VP, Business Development, Joseph Nixon.

The clinical trials are arranged in the following areas:

  • Antibacterials
  • Blood
  • Cancer
  • Eye
  • Metabolic disorders
  • Other genetic conditions

To receive weekly updates about new and ongoing clinical trials, please sign up to the free CMN Newsletter.

 

CRISPR-Cas | TALEN | ZFN | MegaNuclease | CAS-CLOVER | Base Editor | MegaTAL

Bacterial diseases

Indicator
IND Enabling
Phase I
Phase II
Phase III
Urinary Tract Infections, UTI, (NCT04191148)
Open access


Sponsors:
Locus Biosciences
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III

Cardiovascular diseases

Indicator
IND Enabling
Phase I
Phase II
Phase III
Familial Hypercholesterolemia, FH, (NCT05398029)
Sponsors:
Verve Therapeutics, Inc.,
Indicator
IND Enabling
Phase I
Phase II
Phase III

Haematological malignancies (blood cancers)

Indicator
IND Enabling
Phase I
Phase II
Phase III
Acute Myeloid Leukaemia, AML, (ISRCTN14430213)
Sponsors:
Great Ormond Street Hospital for Children NHS Foundation Trust
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Acute Myeloid Leukaemia, AML, (NCT05066165)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT03232619)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
B-Cell Lymphoma, BCL, (NCT05934097)
Sponsors:
Fate Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Non-Hodgkin lymphoma, NHL, (NCT04213469)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
B-cell Non-Hodgkin Lymphoma, NHL, (NCT04649112)
Sponsors:
Precision BioSciences Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
B-Cell Non-hodgkin Lymphoma, NHL, (NCT05631912)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
B-Cell Non-hodgkin Lymphoma, NHL, (NCT06014073)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Diffuse Large B-cell Lymphoma, DLBCL, (NCT04026100)
Sponsors:
The First Affiliated Hospital of Nanjing Medical University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Hematologic Malignancies, (NCT04023071)
Sponsors:
Fate Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (NCT03399448)
Sponsors:
University of Pennsylvania
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (NCT05069935)
Sponsors:
Fate Therapeutics 
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed of Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT02808442)
Sponsors:
Institut de Recherches Internationales Servier
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (2019-003462-40)
Sponsors:
Great Ormond Street Hospital for Children NHS Trust
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT02746952)
Sponsors:
Institut de Recherches Internationales Servier
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT04557436)
Sponsors:
Great Ormond Street Hospital for Children NHS Foundation Trust
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT03229876)
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT03298828)
Sponsors:
Third Military Medical University
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT04037566)
Sponsors:
Xijing Hospital, The Fourth Military Medical University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Haematopoietic Malignancies, (NCT04767308)
Sponsors:
Huazhong University of Science and Technology
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Multiple Myeloma, MM, (NCT03492268)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Multiple Myeloma, MM, (NCT03752541)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
T-Cell Acute Lymphoblastic Leukaemia, T-ALL, (ChiCTR1900025311)
Sponsors:
Xinqiao Hospital of Chongqing, Second Affiliated Hospital of the Army Medical University, Hematology Department
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
T-cell Acute Lymphoblastic Leukaemia, T-ALL, (NCT05397184)
Sponsors:
Great Ormond Street Hospital for Children NHS Foundation Trust
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
T-Cell Lymphoblastic Leukaemia and Lymphoma, (NCT04264078)
Sponsors:
Xinqiao Hospital of Chongqing
Indicator
IND Enabling
Phase I
Phase II
Phase III

Haemoglobinopathies

Beta-Thalassemia, BT, (NCT03728322)
Sponsors:
Allife Medical Science and Technology Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT03655678)
Sponsors:
Vertex Pharmaceuticals Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT04205435)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT04211480)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT05442346)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (2018-001320-19)
Sponsors:
Vertex Pharmaceuticals Incorporated
IndicatorIndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT03167450)
Sponsors:
National Human Genome Research Institute (NHGRI)
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT03653247)
Sponsors:
Sangamo Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT03745287)
Sponsors:
Vertex Pharmaceuticals
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04443907)
Sponsors:
Novartis Pharmaceuticals
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04774536)
Sponsors:
Mark Walters, MD 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04819841)
Discontinued


Sponsors:
Graphite Bio Inc
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04853576)
Sponsors:
Editas Medicine, Inc. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT05329649)
Sponsors:
Vertex Pharmaceuticals Incorporated
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT05456880)
Sponsors:
Beam Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle cell disease, SCD, (NCT05951205)
Sponsors:
Vertex Pharmaceuticals Incorporated
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Trait, (NCT06071377)
Sponsors:
National Alliance for Sickle Cell Centers
IND Enabling
Phase I
Phase II
Phase III
Transfusion-Dependent Beta-Thalassaemia, TDT, (ChiCTR2100052858)
Sponsors:
923rd Hospital of The People's Liberation Army 
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-Dependent Beta-Thalassaemia, TDT, (ChiCTR2100053406)
Sponsors:
The First Affiliated Hospital, Guangxi Medical University  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-Dependent Beta-Thalassemia, TDT, (NCT04390971)
Sponsors:
Institute of Hematology and Blood Diseases Hospital
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Transfusion-Dependent Beta-Thalassemia, TDT, (NCT06041620)
Sponsors:
Institute of Hematology & Blood Diseases Hospital, China
IND Enabling
Phase I
Phase II
Phase III

Haemophilia

Haemophilia B, (NCT02695160)
Sponsors:
Sangamo Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III

Hereditary amyloidosis

Transthyretin Amyloidosis, ATTR, (NCT04601051)
Sponsors:
Intellia Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transthyretin Amyloidosis, ATTR, (NCT06128629)
Sponsors:
Intellia Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III

Immunodeficiencies

Hereditary Angioedema, HAE, (NCT05120830)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III

Inherited eye diseases

Leber Congenital Amaurosis, LCA, (NCT03872479)
Sponsors:
Editas Medicine, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Retinitis Pigmentosa, RP, (NCT05805007)
Sponsors:
Peking University Third Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III

Metabolic disorders

Mucopolysaccharidosis I, MPS I, (NCT02702115)
Sponsors:
Sangamo Therapeutics Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Mucopolysaccharidosis II, MPS II, (NCT03041324)
Sponsors:
Sangamo Therapeutics Inc. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Phenylketonuria, PKU, (NCT05222178)
Sponsors:
Homology Medicines
Indicator
IND Enabling
Phase I
Phase II
Phase III
Refractory Dyslipidemias, (ACTRN12623000809639)
Sponsors:
CRISPR Therapeutics AG
Indicator
IND Enabling
Phase I
Phase II
Phase III
Type 1 Diabetes, T1D, (NCT05210530)
Sponsors:
CRISPR Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Type 1 Diabetes, T1D, (NCT05565248)
Sponsors:
CRISPR Therapeutics AG
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III

Muscular dystrophies

Duchenne Muscular Dystrophy, DMD, (NCT05514249)
Sponsors:
Cure Rare Disease, Inc
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III

Solid cancers

Indicator
IND Enabling
Phase I
Phase II
Phase III
Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies, (NCT03044743)
Sponsors:
Yang Yang, MD, PhD, MSCR, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Breast Cancer, BC, (NCT05812326)
Sponsors:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Epithelial Ovarian Cancer, EOC, (NCT05617755)
Sponsors:
Arsenal Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Esophageal Cancer, (NCT03081715)
Sponsors:
Hangzhou Cancer Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Gastro-Intestinal Cancer, GI, (NCT04426669)
Sponsors:
Intima Bioscience, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Human papillomavirus (HPV) related cervical cancer, (NCT02800369)
Sponsors:
Huazhong University of Science and Technology
Indicator
IND Enabling
Phase I
Phase II
Phase III
Human papillomavirus (HPV) related Cervical Cancer, (NCT03226470)
Sponsors:
Huazhong University of Science and Technology
Indicator
IND Enabling
Phase I
Phase II
Phase III
Human papillomavirus (HPV)-Related Cervical Cancer, (NCT03057912)
Sponsors:
First Affiliated Hospital, Sun Yat-Sen University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Non-small Cell Lung Cancer, NSCLC, (NCT03525782)
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Non-small Cell Lung Cancer, NSCLC, (NCT05566223)
Sponsors:
Intima Bioscience, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Prostate Cancer, (NCT03525652)
Sponsors:
The First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Renal Cell Carcinoma, RCC, (NCT02867332)
Sponsors:
Peking University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Renal Cell Carcinoma, RCC, (NCT04696731)
Sponsors:
Allogene Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Renal Cell Carcinoma, RCC, (NCT06245915)
Sponsors:
Arsenal Biosciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumor Adult, (NCT03545815)
Sponsors:
Chinese PLA General Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumor, Adult, (NCT03747965)
Sponsors:
Chinese PLA General Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumor, Adult, (NCT04976218)
Sponsors:
Chinese PLA General Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT03970382)
Sponsors:
PACT Pharma, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT04551885)
Sponsors:
Fate Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT04842812)
Sponsors:
Second Affiliated Hospital of Guangzhou Medical University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT05239143)
Sponsors:
Poseida Therapeutics 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT05361174)
Sponsors:
Iovance Biotherapeutics, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT05395052)
Sponsors:
Fate Therapeutics 
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT06237881)
Sponsors:
M.D. Anderson Cancer Center
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III

Viral diseases

IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Human Immunodeficiency Virus Infection, HIV, (NCT03164135)
Sponsors:
Affiliated Hospital to Academy of Military Medical Sciences
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Induced Long-term Immunity in COVID-19 Patients, (NCT04990557)
Sponsors:
Mahmoud Ramadan mohamed Elkazzaz
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III

Other rare inherited blood disorders

Severe Pyruvate Kinase Deficiency, PKD, (ChiCTR2300073795)
Sponsors:
Shanghai Children's Medical Center
Indicator
IND Enabling
Phase I
Phase II
Phase III

Other rare inherited disorders

Indicator
IND Enabling
Phase I
Phase II
Phase III
Congenital Hearing Loss, (NCT06025032)
Sponsors:
HuidaGene Therapeutics Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III

Long-term follow-up (LTFU) studies

IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Non-Hodgkin Lymphoma, NHL, (NCT05332054)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Familial Hypercholesterolemia, FH, (NCT06112327)
Sponsors:
Verve Therapeutics, Inc.
IND Enabling
Phase I
Phase II
Phase III
Hematologic and Solid Malignancies, (NCT06208878)
Sponsors:
CRISPR Therapeutics AG
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Hereditary Angioedema, HAE, (NCT06262399)
Sponsors:
Intellia Therapeutics
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Transthyretin Amyloidosis, ATTR, (NCT05697861)
Sponsors:
Intellia Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine